A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
- Summary
- A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors
- Short title
- A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
- Official title
- An Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108 for Injection as Monotherapy or in Combination With Antitumor Therapies in Patients With Advanced Solid Tumors
- Control arm
- Open label
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Active, not recruiting
- Phase
- Phase 1/Phase 2
- Study type
- Interventional
- Completion date
- 2026-03-31
- First posted
- 2022-08-26
- Registry last updated
- 2026-02-04
- Primary completion date
- 2026-03-31
- Start date
- 2022-08-26
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Number of sites
- Registry sponsor category
- Industry
- Lead sponsor
- LaNova Medicines Limited
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05518045
- ClinicalTrials.gov ID
- NCT05518045
- Registry record
- Open registry record
- Allocation
- Not randomised
- Model
- Sequential
- Purpose
- Treatment
- Masking
- No masking
Phase I Dose Escalation:Incidence of adverse events (AEs)
Timeframe: 152 Weeks
Phase I Dose Escalation:Incidence of dose-limiting toxicity (DLT)
Timeframe: 152 Weeks
Phase I Dose Escalation:Incidence of serious adverse event (SAE)
Timeframe: 152 Weeks
Phase I Dose Escalation:Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Objective Response Rate (ORR) Evaluated by Researchers Based on RECIST v1.1
Timeframe: 152 Weeks
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax) for LM-108
Timeframe: 152 Weeks
PK Parameter: Time of Maximum Observed Concentration (Tmax) for LM-108
Timeframe: 152 Weeks
PK Parameter: Area Under the Concentration-time Curve (AUC) for LM-108
Timeframe: 152 Weeks
PK Parameter: Steady State Maximum Concentration (Cmax,ss)
Timeframe: 152 Weeks
PK Parameter: Steady State Minimum Concentration (Cmin, ss)
Timeframe: 152 Weeks
PK Parameter: Systemic Clearance at Steady State (CLss)
Timeframe: 152 Weeks
PK Parameter: Accumulation Ratio (Rac)
Timeframe: 152 Weeks
PK Parameter: Elimination Half-life (t 1/2)
Timeframe: 152 Weeks
PK Parameter: Volume of Distribution at Steady-State (Vss)
Timeframe: 152 Weeks
PK Parameter: Degree of Fluctuation (DF)
Timeframe: 152 Weeks
Incidence of anti-drug antibodies to LM-108
Timeframe: 152 Weeks
Phase I Dose Escalation：Preliminary anti-tumor activity：Objective Response Rate,Duration of Response, Disease Control Rate,Progression-Free Survival,and Overall Survival evaluated according to the Response Evaluation Criteria in Solid Tumors (RECISTv1.1)
Timeframe: 152 Weeks
Phase I Dose Escalation：Correlation between biomarker expression levels (FoxP3, PD-L1, CCR8, CD8) and the anti-tumor activity of LM-108 as monotherapy or in combination with toripalimab.
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Antitumor Activity: Duration of Response (DOR), Disease Control Rate (DCR), Progression-Free Survival (PFS), and Overall Survival (OS) evaluated by investigators based on RECIST v1.1;
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Objective Response Rate (ORR), DOR, DCR, and PFS evaluated by the Independent Review Committee (IRC) based on RECIST v1.1
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Incidence of adverse events (AEs)
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Incidence of serious adverse event (SAE)
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.
Timeframe: 152 Weeks
Phase II Dose Expansion Cohort:Correlation between biomarker expression levels (FoxP3, PD-L1, CCR8, CD8) and the anti-tumor activity of LM-108 as monotherapy or in combination with anti-tumor therapies.
Timeframe: 152 Weeks
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Healthy volunteers
- No
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
- At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
- Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
- Have received anti-CCR8 drug treatment or other clinical study drug or treatment not on the market within 28 days prior to the first dose.
- Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
- Subjects with uncontrolled tumor-related pain.
- Subjects with known brain metastases.
- Uncontrollable clinical third luminal effusion.
- Known history of autoimmune disease.
- Use of any live attenuated vaccines within 28 days.
- Have severe cardiovascular disease.
- Uncontrolled or severe illness.
- History of immunodeficiency disease.
- Active malignancies which are likely to require the treatment.
- Child-bearing potential female.
- Have psychiatric illness or disorders.
- Beijing Cancer HospitalBeijing, China